Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and PD Study of CG-0255 Besylate and Plavix in Healthy Participants
NCT07619885Phase 1Recruiting
- Sponsor
- Shanghai CureGene Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evategrel in acute coronary syndrome (ACS), myocardial infarction (MI), stroke and 1 more (4 arms), sponsored by Shanghai CureGene Pharmaceutical. Primary endpoint: Pharmacokinetics of the active metabolite CG-0236 at Day 7. Started Jun 2026; status: recruiting.
02
Drugs
evategrel
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)strokePeripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07619885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619885.